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INTRODUCTION
Executive Function (EF) is the higher order, self-regulatory, 
cognitive processes for monitoring and control of thought and 
behaviour, associated with the frontal lobes [1,2]. Executive defi cits 
could result from damage to the frontal lobe, or disruptions to the 
connective pathways mediated by the frontal lobes [3]. Over the past 
two decades, research has investigated apparent similarities between 
symptoms of executive dysfunction and symptoms of clinical anxiety 
and depression. According to the Diagnostic and Statistical Manual 
of Mental Disorders 5th Edition [4], individuals with depression and 
anxiety typically present with defi cits in motivation/volition, problem 
solving, planning, concentration, emotional stability, psychomotor 
disturbances and perseverative thoughts; all of these are fundamental 
defi cits in EF [5,6]. Depressed  individuals frequently exhibit 
hypoactivity in cortical regions of the frontal lobes and prefrontal and 
anterior cingulate, which has been linked with the lack of volition (or 
planned decisive action) that frequently accompanies  depression 
[7]. Anxiety disorders have sometimes been characterized by 
problems with inhibition which is defi ned as the inability to inhibit a 
prepotent response [8]. For example, panic disorder is characterized 
by problems with ignoring stimuli [9], as is Obsessive Compulsive 
Disorder (OCD). Recent meta-analyses have confi rmed that both 
anxiety and depression are associated with a wide range of signifi cant 
defi cits in EF. 
A large meta-analysis [10] compared participants with major 
depressive disorder with healthy controls on neuropsychological 
measures of EF. Depression was reliably associated with signifi cant 
impairments in all domains of EF measured (d = 0.45–0.58), 
including inhibition (of a habitual response), shift ing (adapting to 
diff erent sets of rules), updating (of relevant information in working 
memory), verbal working memory, visuospatial working memory, 
planning, and verbal fl uency. Associations could not be accounted 
for by processing speed. Defi cits were greater in patients with more 
severe depression, and those taking psychotropic medications. Some 
evidence suggested there were greater impairments in tasks requiring 
inhibition than other domains. Other meta-analyses have confi rmed 
that major depression is associated with defi cits across numerous 
domains of EF [11,12].
Recent meta-analyses have examined the relationship of EF with 
specifi c anxiety disorders. Snyder, Raiser and Heller [13] found that, 
compared with healthy controls, a diagnosis of OCD was associated 
with broad range of EF impairments including inhibition, shift ing, 
updating, verbal and visuospatial working memory or planning (with 
most eff ect sizes d between 0.3 and 0.5). None of these associations 
could be accounted for by general motor slowness or by comorbid 
depression. Depression was a signifi cant moderator on one task 
measure, the Stroop interference task; samples with comorbid 
depression had less severe problems inhibiting an established 
response on this task. Another meta-analysis [14] found that patients 
with OCD were signifi cantly impaired in EF and a wide range of other 
cognitive domains, independent of symptom severity, medication 
status or co-morbid disorders. Th ere seemed to be a larger defi cit in 
planning ability than other domains.
Scott et al. [15] conducted a meta-analysis of 60 studies on 
neurocognitive defi cits associated with Post-Traumatic Stress 
Disorder (PTSD). Compared to healthy controls, patients with PTSD 
had signifi cant defi cits in a wide range of cognitive abilities including 
EF (d = .45). A systematic review [16] of the role of EF in PTSD and, 
across 18 studies, found that, in comparison with trauma-exposed 
controls and healthy controls, participants with PTSD showed 
signifi cantly impaired EF. Th ere were greater impairments in EF for 
participants with comorbid depression. 
A systematic review of studies of panic disorder [17] did not fi nd 
support for the presence of an impairment in EF, nor other areas 
of cognitive functioning; however, the fi ndings were inconclusive 
due to small sample sizes in studies. Isolated studies investigating 
EF defi cits associated with other anxiety disorders report mixed 
results. For instance, one study of Generalized Anxiety Disorder 
in later life [18], reported no defi cits in EF associated with anxiety 
unless there was comorbid depression. Another study [19] reported 
defi cits in EF associated with generalized social anxiety disorder. In 
summary, despite some mixed results, recent large meta-analyses 
confi rm signifi cant defi cits in executive defi cits associated with 
major depression and anxiety diagnoses of OCD and PTSD. Given 
its relationship with anxiety and depression, attention has turned 
to the role of executive dysfunction in predicting responsiveness to 
treatment.
Both pharmacological and psychological interventions have 
been demonstrated to be eff ective in treating depression [20-22] 
and anxiety disorders [23]. Th ere have been two meta-analyses of 
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predictors of treatment response for depression. A meta-analysis 
of predictors of treatment outcomes (including pharmacological, 
psychological and care management) for depression [24], found 
that poor treatment outcomes were predicted by severity of baseline 
depression, EF defi cits and presence of co-morbid anxiety. Th ere were 
mixed results about whether the domain of response inhibition was a 
signifi cant predictor. Another meta-analysis [25] examined whether 
six domains of EF extracted from eight studies predicted short-term 
eff ectiveness of pharmacological interventions. Only performance 
related to the planning and organisation tasks predicted treatment 
response; other domains including response inhibition did not. Th is 
is consistent with early research linking depression with problems 
in volition [7]. Using positron emission tomography with inpatients 
with major depression, Mayberg et al.  [26] found that responsiveness 
to antidepressant medication was predicted by metabolism in the 
 rostral anterior cingulate area of the brain which is deeply involved 
in action regulation [27]. Gyurak et al.  [28] used magnetic resonance 
imaging to monitor frontoparietal activation in patients with major 
depression, and found that frontoparietal activation, during the 
response inhibition task (but not selective attention or working 
memory tasks) predicted later remission with antidepressant 
treatment. Overall these studies suggest that inhibition may be central 
in predicting treatment eff ectiveness for depression, and that volition 
(planning and organisation) may also play a role.
At present, research results are inconclusive regarding whether 
EF predicts treatment outcomes for anxiety disorders. Two studies of 
generalized anxiety disorder in later life found that pre-treatment EF 
did not predict treatment outcome, although changes over time in EF 
were associated with reductions in anxiety [29,30]. Johnco, Wuthrich 
and Rapee [31] found that pre-treatment cognitive fl exibility did 
not predict outcomes in anxiety or depression following CBT for 
older participants. Similarly, EF did not predict treatment outcomes 
following CBT for participants with OCD [32], although non-
recovered patients had lower pre-treatment social functioning than 
recovered patients. In summary, research has not been successful at 
predicting treatment outcomes for anxiety from pre-treatment EF.
Th e present study investigates whether EF predicts treatment 
outcomes following CBT for outpatients with diagnoses of depression 
and anxiety. Most studies of EF to date have used neurological 
imaging or neuropsychological tests of EF. Although highly 
eff ective, these intensive assessments may not always be available 
to clinicians in all settings. Previous research has investigated the 
utility of psychometric questionnaires including Th e Dysexecutive 
Questionnaire (DEX) [33,34] to measure executive dysfunction. 
Shaw, Oei and Sawang  [35] investigated the factor structure of 
the DEX with community, depressed, anxious, and neurologically 
impaired samples and found that that a factor structure including 
factors of Inhibition, Volition, and Social Regulation, was superior to 
other factor models (DEX-R). Volition is the formation of intention 
and self-awareness [2]. Inhibition is the ability to inhibit a prepotent 
response in order to make a less automatic but task-relevant response 
[37]. Social regulation refl ects awareness and concern for social rules 
[35]. Oei, Shaw and Healy [34] compared EF using the DEX-R in 
neurological, psychiatric patients and general community members. 
Th ey found that patients with anxiety had greater EF defi cits than all 
other groups and greater defi cits in inhibition and volition; patients 
with depression reported greater executive dysfunction in volition 
than the community group. However, given the high co-morbidity 
between depression and anxiety disorders (50 to 60%) [36], it is 
unclear how comorbidity infl uenced results reported by Oei et al. 
[34].
Th e current study investigates whether EF, measured by DEX-R, 
predicts treatment outcomes for anxiety and depression following 
CBT for outpatient with diagnoses of major depression or an anxiety 
disorder. A further aim is to investigate whether EF concurrently 
predicts symptom severity in depression and anxiety aft er controlling 
for comorbidity. We hypothesized that 1) aft er controlling for 
comorbidity, that executive dysfunction, would concurrently predict 
both anxiety and depression; 2) lower levels of pre-treatment executive 
dysfunction would predict better treatment outcomes for both 
anxiety and depression 3) that defi cits in pre-treatment inhibition 
would predict both concurrent and post-treatment outcomes for 
anxiety and 4) that defi cits in pre-treatment volition would predict 
both concurrent and post-treatment outcomes for user.
METHOD
Participants 
Th e sample consisted of 206 outpatients with a primary diagnosis 
of either anxiety (71.4%) or major depression (28.6%) referred to a 
private psychiatric hospital for Group Cognitive Behavioral Th erapy 
(GCBT). Inclusion criteria were a single primary diagnosis of either 
anxiety or depression. No patients with a diagnosis of psychosis 
were included. All diagnoses were made by psychiatrists according 
to the DSM-IV-TR [38] prior to referral. No psychiatric patient 
was excluded on the basis of medication status. Anxiety diagnoses 
included panic disorder (39.3%), generalized anxiety disorder 
(20.9%), Post-Traumatic Stress Disorder (PTSD) (10.1%), and other 
anxiety disorders (1%). Th ey were 64.5% female and 35.5% male 
with an average age of 43.5 years. For 94.9% of participants, English 
was the primary language. Post-treatment data was available for 144 
outpatients who attended the fi nal CBT session (69.9%). Th ere were 
no signifi cant diff erences between completers and non-completers 
on age (F [1, 204] = 1.97, p = .162), gender (F [1, 204] = 0.79, p = 
.376) educational level (F [1, 204] = 0.27, p = .602), nor pre-treatment 
anxiety (F [1, 204] = 1.59, p = .209), depression (F [1, 204] = 0.94, p = 
.335 or EF DEX-R (F [1, 204] = 2.37, p = .125).
Measures
All measures were written in English.
Dysexecutive functioning: EF was assessed pre-treatment using 
the 15-item revised Dysexecutive Questionnaire (DEX-R) [35]. Item 
responses range from 0 (never) to 4 (very oft en) with higher scores 
indicating greater dysfunction. Total DEX-R had a Cronbach’s  
of .87. EF subscales of Inhibition (e.g. ability to inhibit responses, 
confabulation, impulsivity), Volition (e.g. planning problems, apathy 
and lack of drive) and Social Regulation (e.g. lack of concern for social 
rules) were calculated aft er Shaw et al. [35]. Internal consistency 
was good for Inhibition ( = .79) and Volition ( = .81). Internal 
consistency as measured by Cronbach’s alpha was low for Social 
Regulation ( = .56). However, given low scores on Cronbach’s alpha 
are common for scales with few items, we also calculated mean inter-
item correlation for Social Regulation (r = .39); this was within the 
recommended range [39]. 
Depression and anxiety symptomatology: Two well established 
and validated scales were utilized: the Zung Self-Rating Depression 
Scale (SDS) [40] and the Beck Anxiety Inventory (BAI) [41]. Th e 
Zung SDS has demonstrated acceptable reliability, and predictive 
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validity as a screening measure for diagnosis of depression [42]. It, 
correlates well (0.69) with the treating physician’s global ratings 
of depressed outpatients during treatment [43]. Th e BAI is a well-
established measure demonstrated to have sound psychometric 
properties including reliability, concurrent and construct validity 
[41]. For the current sample, the SDS had a Cronbach’s α of .84 for the 
pre-treatment scores and .90 for post-treatment scores; Cronbach’s α 
for the BAI was .94 for both pre-treatment scores and post-treatment 
scores. 
Procedure: Ethical clearance was received from Th e University of 
Queensland and Toowong Private Hospital. As in our previous papers 
[34,35], participants were recruited from an outpatient psychiatric unit 
at the Toowong Private Hospital. All patients were referred to the CBT 
Unit for GCBT and gave informed written consent to participation in 
the study prior to their involvement. Th e GCBT programs have been 
described in previous publications [44-46]. Each group involved, on 
average, eight patients. Treatment consisted of eight 3.5-hour sessions 
over 4 weeks. Th e manualized GCBT program for anxiety comprised 
psycho-education, self-monitoring, relaxation exercises, cognitive 
restructuring, interoceptive and in vivo exposure, problem solving, 
maintenance and relapse prevention. Th e manualized GCBT program 
for depression covered psycho-education, self-monitoring, relaxation, 
behavioral activation, cognitive monitoring and restructuring, 
problem solving, maintenance and relapse prevention. Th e anxiety 
and depression programs are documented in unpublished workbooks 
by Oei at Toowong Private Hospital. All groups were facilitated by 
a clinical psychologist with over 20 years of GCBT experience and 
a psychiatric nurse with extensive experience in GCBT. Participants 
completed DEX-R, anxiety and depression scales prior to treatment 
and anxiety and depression scales aft er GCBT.
Statistical Analyses
We fi rst conducted a MANOVA to compare pre-treatment 
diff erences on anxiety, depression and DEX-R scores for patients 
with an anxiety diagnosis compared with patients with a depression 
diagnosis; this was then repeated substituting DEX-R subscales. To 
determine whether executive dysfunction could predict symptom 
severity in anxiety and depression aft er taking into account 
comorbidity, we conducted a series of stepwise Hierarchical 
Multiple Regression Analyses (HMR) through SPSS, using either 
pre-treatment anxiety or pre-treatment depression as the outcome 
variable, as described by Tabachnick and Fidell [47]. When pre-
treatment anxiety was the outcome variable, the order of entry of 
predictor variables was as follows: Step 1 pre-treatment depression; 
Step 2 primary diagnostic category (anxiety versus depression); Step 
3 executive dysfunction; Step 4 two-way product terms involving 
executive dysfunction and diagnostic category. When pre-treatment 
depression was the outcome variable, pre-treatment depression was 
substituted at Step 1, and pre-treatment anxiety was substituted at 
Step 2. We centred each variable before calculating product terms to 
avoid problems of multicollinearity associated with utilizing product 
terms in regression [48].
We used a parallel procedure to test if pre-treatment DEX-R scales 
predicted treatment outcomes in depression and anxiety following 
GCBT. We fi rst checked for change in depression and anxiety scores 
between pre and post-treatment using ANOVAs. We used HMR to 
test whether DEX-R scales would predict post-treatment anxiety aft er 
controlling for pre-treatment anxiety and primary diagnosis, and 
whether DEX-R scales would predict post-treatment depression aft er 
controlling for pre-treatment depression and primary diagnosis. 
RESULTS
Preliminary Analyses
 Missing values (< 5% for each variable) were scattered randomly 
throughout the data so did not pose any methodological problems 
[49]. Several DEX-R scales, depression and anxiety scales had a 
signifi cant positively skew (Z > 1.96) and were kurtosed, which is 
not uncommon with clinical data [50]. However multiple regression 
assumes normality [47], so we transformed the data. Analyses 
of transformed data yielded the same pattern of results as the 
untransformed data, so the untransformed analyses were reported.
Comparison of Anxious and Depressed Groups on 
Clinical Measures
We conducted MANOVAs to check diff erences in pre-treatment 
scores for patients with an anxiety diagnosis compared with patients 
with depression. Th e anxious group had higher scores than the 
depressed group on anxiety (F [1, 203] = 58.20, p < .001), depression 
(F [1, 203] = 24.70, p < .001), total DEX-R (F [1, 203] = 25.05, p < 
.001) and DEX-R subscales of Inhibition (F [1, 203] = 17.46, p < .001), 
Volition (F [1, 203] = 27.37, p < .001), but not Social Regulation (F [1, 
203] = 0.70, p = .405). 
Executive Dysfunction as a Predictor of Pre-Treatment 
Anxiety 
Table 1: Means, Standard Deviations and Inter-correlations between variable.
Variables Mean (SD) n 1. 2. 3. 4. 5. 6. 7.
1. Pre-treatment 
anxiety 23.49 (13.25) 206 -
2. Post-treatment 
anxiety 15.79 (12.21) 143
.62
*** -
3. Pre-treatment 
depression 52.73 (9.48) 206
.61
***
.56
*** -
4. Post-treatment 
depression 46.17 (11.05) 144
.45
***
.70
***
.69
*** -
5. DEX-R total 
score 24.39 (10.30) 206
.52
***
.45
***
.54
***
.48
*** -
6. DEX-R 
Inhibition 8.18 (4.61) 206
.47
***
.28
**
.36
***
.27
**
.85
*** -
7. DEX-R 
Volition 13.76 (5.82) 206
.50
***
.47
***
.64
***
.55
***
.91
***
.59
*** -
8. DEX-R Social 
Regulation 2.46 (1.97) 205
.15
*
.23
**
.09 .20
**
.57
***
.36
***
.40
***
* p < .05  ** p < .01  *** p < .001
Table 1 shows means, standard deviations and bivariate correlations. There 
were signiﬁ cant correlations between DEX-R scales, anxiety and depression 
measures.
Table 2: DEX-R as a Predictor of Concurrent Anxiety.
Step
Predictor 
Variables 
Added
Anxiety Score
B [95% CI] SEB  R2(adj) ∆ R2
F 
Change
1. Depression Score 0.57 [0.41; 0.74] 0.08
.41
***
.37
*** .38
123.08
***
2. Diagnostic Group -9.49 [-12.82; -6.16] 1.69
-.32
***
.45
*** .08
30.87
***
3. DEX-R 0.24 [0.09; 0.39] 0.08 .19**
.48
***
.03 11.59
**
4. DEX-R x Diagnosis -0.43 [-0.75; -0.11] .16
-.14
* .50 .02
6.85
*
* p < .05  ** p < .01  *** p < .001 
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Tables 2 and 3 show HMR, using total DEX-R to predict 
concurrent anxiety, aft er controlling for depression. Pre-treatment 
depression scores at Step 1 and diagnostic category at Step 2 both 
predicted pre-treatment anxiety scores (p < .001). At Step 3, inclusion 
of the DEX-R total scores improved prediction of pre-treatment 
anxiety scores (p = .001). Th ere were further improvements to the 
model with inclusion of 2-way product terms at Step 4 (p = .010). 
Th e variables which accounted for unique variance in anxiety scores 
were depression scores ( p < .001), diagnostic category (
p < .001), DEX-R total scores (  p = .002) and DEX-R 
X Diagnosis (   p = .010). So, higher anxiety scores were 
predicted by an anxiety diagnosis, higher scores on DEX-R and the 
interaction term. Figure 1 graphs the signifi cant two-way interaction. 
Th ere is a steeper gradient for the relationship between DEX-R and 
anxiety for patients with an anxiety diagnosis than for patients with 
a depression diagnosis, meaning that higher levels of DEX-R predict 
proportionately higher levels of anxiety for anxiety patients than for 
depression patients.
Table 3 shows that when DEX-R sub-scales (instead of total 
DEX-R) were entered at Step 3, this still signifi cantly improved 
prediction of concurrent anxiety (F [3, 199] = 6.42, p < .001) but 
inclusion of product terms at Step 4 made no further improvement 
(F [3, 196] = 2.10, p = .102). Th e variables accounting for unique 
variance in pre-treatment anxiety scores were depression scores (
p < .001), diagnostic category (p < .001) and DEX-R 
Inhibition (p = .001). So, higher pre-treatment anxiety scores 
were predicted by an anxiety diagnosis and higher scores on DEX-R 
Inhibition. 
Executive Dysfunction as a Predictor of Pre-Treatment 
Depression 
Table 4 shows the HMR using total DEX-R to predict depression 
scores aft er controlling for anxiety scores. At Step 1, anxiety scores 
predicted pre-treatment depression (p < .001) but diagnostic category 
at Step 2 did not (p = .417). Inclusion of whole-scale DEX-R at Step 
3 improved the model (p < .001) but inclusion of product terms at 
Step 4 made no further improvement (p = .358). Th e variables which 
accounted for unique variance in depression scores were anxiety 
scores ( p < .001) and DEX-R total score ( p < .001). 
So, higher pre-treatment depression scores were predicted by higher 
scores on DEX-R. 
Table 5 shows the HMR for depression scores using the DEX-R 
subscales. Inclusion of DEX-R subscales at Step 3 signifi cantly 
improved prediction of pre-treatment depression (p < .001), but 
inclusion of the product terms at Step 4 made no further improvement 
(p =.176). Th e variables which accounted for unique variance in 
depression scores were DEX-R Volition (p < .001), anxiety 
score (p < .001), and DEX-R Social Regulation (p = 
.014). So, higher depression scores were predicted by higher scores in 
DEX-R Volition, and lower scores on DEX-R Social Regulation. 
Evaluation of GCBT Treatment Outcomes
We tested for reductions in depression and anxiety 
symptomatology following GCBT. Means and standard deviations 
for pre and post measures for anxiety and depression are displayed 
in Table 1. Th ere were signifi cant reductions in anxiety (t [142] = 
8.66, p < .001), and depression (t (143) = 7.60, p < .001). As there 
was no control group in the clinical setting, we used a pre-post bias 
correction to calculate eff ect size recommended by Morris and De 
Shon [51], resulting in medium eff ect sizes for anxiety (d = 0.53) and 
depression, (d = 0.43).
DEX-R Scales as Predictors of Treatment Outcomes for 
Anxiety
Table 6 and 7 show HMR using DEX-R scales to predict post-
treatment anxiety, aft er controlling for pre-treatment anxiety. 
Table 3: DEX-R Subscales as Predictors of Concurrent Anxiety.
Step Predictor Variables Added
Anxiety Score
B [95% CI] SEB  R2(adj)
∆ 
R2
F 
Change
1. Depression Score 0.62 [0.43; 0.81] 0.10 .45***
.37
*** .38
122.34
***
2. Diagnostic Group -9.98 [-12.39; -5.58] 1.73 -.31***
.45
*** .08
30.48
***
3.
DEX-R Inhibition 0.65 [0.29; 1.00] 0.18 .23***
.49
*** .05
6.42
***DEX-R Volition -0.06 [-0.42; 0.30] 0.18 -.03
DEX-R Social 
Regulation 0.09 [-0.66; 0.84] 0.38 .01
4.
DEX-R Inhibition x 
Diagnosis -0.23 [-1.09; 0.63] 0.44 -.03
.50
*** .02 2.10
DEX-R Volition x 
Diagnosis -0.35 [-1.03; 0.32] 0.34 -.07
DEX-R Social Reg 
x Diagnosis -0.98 [-2.67; 0.72] 0.86 -.06
* p < .05  ** p < .01  *** p < .001
Figure 1: Interaction of DEX-R and Diagnostic Category in Prediction of 
Anxiety
Table 4: DEX-R as a Predictor of Concurrent Depression.
Step Predictor Variables Added
Depression Score
B [95% CI] SEB  R2(adj) ∆ R2
F 
Change
1. Anxiety Score 0.33 [0.23; 0.42] 0.05 .46***
.37
*** .38
123.08
***
2. Diagnostic Group 0.15 [-2.57; 2.86] 1.38 .01 .37*** .00 0.66
3. DEX-R 0.28 [0.17; 0.40] 0.06 .31***
.44
*** .07
24.15
***
4. DEX-R x Diagnosis 0.12 [-0.13; 0.37] .13 .05 .44 .00 0.89
* p < .05  ** p < .01  *** p < .001
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For both regressions, inclusion of pre-treatment anxiety at Step 1 
signifi cantly contributed to the prediction of post-treatment anxiety 
(p < .001) but inclusion of diagnostic group at Step 2 did not (p = .363). 
Table 6 shows that inclusion of DEX-R total score at Step 3 improved 
prediction of post-treatment anxiety (p = .011), but inclusion of the 
interaction term at Step 4 did not (p = .993). At Step 4, pre-treatment 
anxiety ( p < .001), and DEX-R total score ( p = .011), 
accounted for signifi cant unique variance in post-treatment anxiety. 
Th at is, better treatment outcomes in anxiety were predicted by lower 
levels of pre-treatment anxiety and lower DEX-R total score. Table 
7 shows that when DEX-R subscales were used instead of DEX-R 
total score at Step 3, DEX-R subscales improved prediction of pre-
treatment anxiety (p = .003), but inclusion of product terms at Step 4 
did not. Variables accounting for unique variance in post-treatment 
anxiety were pre-treatment anxiety (   p < .001), DEX-R 
Volition ( p = .008) and DEX-R Social Regulation ( p 
= .020). Th at is, better treatment outcomes for anxiety were predicted 
by lower levels of pre-treatment anxiety, DEX-R Volition and DEX-R 
Social Regulation.
DEX-R Scales as Predictors of Treatment Outcomes for 
Depression
Tables 8 and 9 show HMR, using DEX-R scales, to predict post-
treatment outcomes for depression scores. For both regressions, 
inclusion of pre-treatment depression at Step 1 signifi cantly 
contributed to prediction of post-treatment depression (p < .001) but 
inclusion of diagnostic group at Step 2 did not (p = .322). Inclusion 
of neither total DEX-R nor DEX-R subscales at Step 3 signifi cantly 
improved the model, nor did inclusion of the interaction terms at 
Step 4. However, examination of -weights reveals that DEX-R Social 
Regulation predicted signifi cant unique variance in post-treatment 
depression ( p = .034), as did pre-treatment depression (
p < .001). Th at is better treatment outcomes in depression were 
Table 5:  DEX-R Subscales as Predictor of Concurrent Depression.
Step Predictor Variables Added
Depression Score
B [95% CI] SEB  R2(adj) ∆ R2
F 
Change
1. Anxiety Score 0.29 [0.20; 0.38] 0.04 .40***
.37
***
.38 122.34
***
2. Diagnostic Group 1.13 [-1.34; 3.60] 1.25 .05 .37***
.00 0.67
3.
DEX-R Inhibition -0.19 [-0.44; 0.06] 0.13 -.09
.55
*** .18
26.95
***
DEX-R Volition 0.94 [0.74; 1.15] 0.11 .58***
DEX-R Social 
Regulation
-0.76 [-1.26; 
-0.27] 0.25
- 
0.16
**
4.
DEX-R Inhibition x 
Diagnosis 0.48 [-0.10; 1.06] 0.30 .10
.55
*** 1.6 1.67
DEX-R Volition x 
Diagnosis 0.06 [-0.40; 0.53] 0.24 .02
DEX-R Social Reg x 
Diagnosis -0.97 [-2.12; 0.18] 0.58 -.09
* p < .05  ** p < .01  *** p < .001
Table 6: DEX-R as a Predictor of Post-Treatment Anxiety.
Step
Predictor 
Variables Added
Post Treatment Anxiety Score
B [95% CI] SEB  R2(adj)
∆ 
R2
F 
Change
1. Pre Treatment Anxiety 0.49 [0.33; 0.65] 0.08
.50
***
.38
*** .38
81.80
***
2. Diagnostic Group -1.09 [-5.70; 3.52] 2.33 -.04 .38*** .00
0.83
3. DEX-R 0.25 [0.06; 0.44] 0.10 .20*
.40
***
.03 6.65
*
4. DEX-R x Diagnosis 0.00 [-0.43; 0.43] 0.22
.00 .40
*** .00
0.00
* p < .05  ** p < .01  *** p < .001
Table 7: DEX-R Subscales as Predictors of Post-Treatment Anxiety.
Step Predictor Variables Added
Post Treatment Anxiety Score
B [95% CI] SEB  R2(adj)
∆ 
R2
F 
Change
1. Pre Treatment Anxiety Score 0.47 [0.31; 0.63] 0.08
.48
***
.38
*** .38
81.80
***
2. Diagnostic Group -1.54 [-6.12; 3.05] 2.32 -.06 .38*** .00
0.83
3.
DEX-R Inhibition -0.26 [-0.71; 0.20] 0.23 -.09
.43
*** .06
4.82
**DEX-R Volition 0.49 [0.13; 0.85] 0.18 .24**
DEX-R Social 
Regulation 1.11 [0.18; 2.04] 0.47
.16
*
4.
DEX-R Inhibition x 
Diagnosis 0.84 [-0.21; 1.89] 0.53 .13
.43
*** .02 1.39
DEX-R Volition x 
Diagnosis -0.47 [-1.26; 0.33] 0.40 -.10
DEX-R Social Reg 
x Diagnosis -0.96 [-3.07; 1.15] 1.07 -.07
* p < .05  ** p < .01  *** p < .001
Table 8: DEX-R as a Predictor of Post-Treatment Depression.
Step Predictor Variables Added
Post Treatment Depression Score
B [95% CI] SEB  R2(adj) ∆ R2
F 
Change
1. Pre-Treatment Depression Score 0.71 [0.53; 0.88] 0.09
.61
***
.47
*** .48
122.53
***
2. Diagnostic Group -1.86 [-5.51; 1.79] 1.84 -.08 .47*** .00 0.99
3. DEX-R 0.12 [-0.06; 0.29] 0.09 .10 .48*** .01
2.14
4. DEX-R x Diagnosis -0.16 [-0.52; 0.20] .18 -.06
.48
*** .00 0.74
* p < .05  ** p < .01  *** p < .001
Table 9: DEX-R Subscales as Predictors of Post-Treatment Depression.
Step Predictor Variables Added
Post Treatment Depression Score
B [95% CI] SEB β R
2
(adj)
∆ 
R2
F 
Change
1. Pre Treatment Depression Score 0.71 [0.50; 0.92] 0.10
.61
***
.47
*** .48
122.53
***
2. Diagnostic Group -2.39 [-6.14; 1.35] 1.89 -.10 .47*** .00
0.99
3.
DEX-R Inhibition -0.16 [-0.56; 0.23] 0.20 -.06
.49
*** .03
2.22DEX-R Volition 0.15 [-0.25; 0.55] 0.20 .08
DEX-R Social 
Regulation 0.88 [0.07; 1.69] 0.41
.15
*
4.
DEX-R Inhibition x 
Diagnosis -0.23 [-1.15; 0.69] 0.47 -.04
.48
*** .01 0.55
DEX-R Volition x 
Diagnosis -0.06 [-0.76; 0.63] 0.35 -.01
DEX-R Social Reg 
x Diagnosis -0.76 [-2.58; 1.06] 0.92 -.06
* p < .05  ** p < .01  *** p < .001
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predicted by lower pre-treatment scores in depression and social 
regulation problems.
DISCUSSION
Th is study aimed to test whether EF, as measured by DEX-R, was 
related to concurrent symptom severity of depression and anxiety 
aft er controlling for comorbidity, and whether it could predict 
treatment outcomes following GCBT for outpatients with depression 
and anxiety disorders. Consistent with our hypothesis and previous 
research [10,13], executive dysfunction predicted concurrent 
symptom severity in anxiety aft er controlling for comorbid 
depression, and concurrent depression aft er controlling for comorbid 
anxiety. Analyses using subscales were consistent with hypotheses 
that, aft er controlling for comorbidity, problems in inhibition would 
be concurrently associated with anxiety, and problems with volition 
associated with depression. 
Consistent with our predictions, DEX-R signifi cantly predicted 
reductions in anxiety following participation in a GCBT. However, 
contrary to predictions, DEX-R did not predict treatment outcomes 
for depression. Th e prediction of outcomes from DEX-R subscales 
also diff ered from hypotheses. We will fi rst discuss the pattern DEX-R 
of subscales in the prediction of concurrent anxiety and depression, 
then in the prediction of treatment outcomes. 
Consistent with our hypothesis and previous literature [9], aft er 
controlling for comorbid depression, severity of pre-treatment anxiety 
was predicted by executive defi cits in inhibition. Also, consistent with 
our hypotheses, aft er controlling for comorbid anxiety, depression 
scores were predicted by executive problems with volition; this is 
consistent with previous reports that patients with depression have 
diffi  culties in organization and initiating goal-directed activities [7]. 
Th is suggests that fi ndings by Oei et al. [34] that patients with anxiety 
had greater defi cits in Volition as well as Inhibition may have been 
due to comorbid depression. Th e current study shows that, aft er 
controlling for comorbidity, problems with volition are associated 
with depression but not anxiety. 
Additional to our hypotheses, aft er controlling for comorbid 
anxiety, severity of pre-treatment depression was also predicted 
by lower scores on social regulation. Social Regulation refl ects a 
lack of concern in social situations. So, higher levels of depression 
symptomatology were predicted by higher levels of social concern, 
rather than indiff erence to social rules typical of executive 
dysfunction. Th ere is little previous literature examining the 
relationship between concern for social rules and depression. Oei 
et al. [34] reported no signifi cant diff erences in Social Regulation 
between depression patients and a community sample. Perhaps the 
relationship between depression and high social concern in this study 
refl ects social discomfort. Zahn et al. [52] found that depression 
patients in remission retrospectively reported high levels of self-
disgust, guilt and shame. Collazzoni et al.  [53] found that humiliation 
diff erentiated clinically depressed subjects, from a carefully matched 
non-clinical sample. It is possible then that the relationship between 
social regulation and depression in this study may refl ect social 
discomfort and embarrassment. 
In this study higher pre-treatment anxiety scores were predicted, 
not only by higher scores on DEX-R, but also by the interaction of 
DEX-R and diagnosis. Th at is, higher levels of executive dysfunction 
predicted proportionately higher levels of anxiety for anxiety 
patients than for depression patients. Th is pattern of results can be 
interpreted through considering diff erences in scores on clinical 
measures for patients with a primary diagnosis of anxiety versus 
depression. Patients with an anxiety diagnosis had higher scores than 
depression patients, on anxiety, depression, DEX-R total score, and 
problems with Inhibition. Th is suggests that patients with a primary 
diagnosis of anxiety were more likely to have a secondary diagnosis of 
depression than vice versa. Th is is consistent with previous fi ndings 
that depression can develop as a secondary issue to anxiety [54] and 
to mild to moderate traumatic brain injury [55]. 
Analyses using DEX-R scales to predict treatment outcomes in 
anxiety showed some departures from hypotheses. Consistent with 
hypotheses, total DEX-R scores predicted treatment outcomes in 
symptom severity for anxiety. However, contrary to predictions, 
and previous literature linking inhibition problems with anxiety [9], 
Volition and Social Regulation rather than Inhibition predicted poorer 
treatment outcomes in anxiety. Why might this be? Problems with 
response inhibition are common for patients with anxiety. However, 
CBT teaches patients with anxiety to better manage their automatic 
responses. So perhaps GCBT helped treat problems with inhibiting 
responses common to anxiety and executive dysfunction, by enabling 
patients to respond in more fl exible ways to aversive stimuli. In the 
current sample, depression was higher for patients with an anxiety 
diagnosis than for patients with a depression diagnosis. Perhaps 
comorbid depression associated with volition problems predicted 
poor outcomes1. Patients with comorbid depression may not have 
had issues related to depression addressed within the time frame 
given that the GCBT program was intended primarily to address 
issues associated with anxiety. Defi cits in planning and initiating 
associated with lower scores in in Volition may have been associated 
with poorer participation in group activities and homework for these 
outpatients, which aff ected treatment outcomes. 
Regressions using DEX-R scales to predict treatment outcomes 
in depression also showed some unexpected results. Contrary to 
hypotheses, neither total DEX-R score, nor problems with Volition 
predicted post-treatment  depression scores. Th e sample for this study 
included psychiatric outpatients with major depressive disorder. As 
lack of volition is a key symptom of depression [7], patients would 
have had major defi cits in volition. Th erefore, eight sessions of GCBT 
over four weeks of GCBT may have been insuffi  cient to produce 
signifi cant change, which may have eff ected prediction of treatment 
outcomes by DEX-R. Although this explanation seems plausible, 
further vigorous research is needed. Th e only DEX-R subscale which 
predicted treatment outcomes in depression was Social Regulation, 
with poorer treatment outcomes predicted by greater defi cits in social 
awareness characteristic of executive dysfunction. Perhaps a lack of 
concern about group rules impeded participation in GCBT. 
Th is study investigated executive dysfunction measured by 
the DEX-R questionnaire with psychiatric outpatients diagnosed 
with anxiety or depression. Executive dysfunction predicted both 
concurrent anxiety and depression aft er controlling for comorbidity. 
Problems in inhibiting responses predicted concurrent anxiety; 
problems with Volition and Social Regulation predicted concurrent 
depression. Greater EF problems in Volition and Social Regulation 
predicted poorer treatment outcomes for anxiety. Strengths of the 
study included a real-world sample and a longitudinal data set. 
Weaknesses included reliance on self-report measures, which are 
limited by individuals’ insight into their own abilities. A further 
1 Indeed when regressions were repeated controlling for depression as well as 
anxiety at Step 1, Volition no longer predicted treatment outcomes.
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limitation is that no control group was utilized. 
Th e fi ndings suggest that screening patients with anxiety for 
executive dysfunction may predict receptivity to CBT. Social regulation 
was relevant for treatment outcomes for both patients with depression, 
and patients for anxiety. Checking social regulation scores prior to 
CBT may identify individuals who may have diffi  culty participating 
in a group and may benefi t more from individual therapy. Individuals 
with executive dysfunction may benefi t from incorporation of 
neurocognitive training strategies along with traditional approaches 
in order to improve therapeutic gains. Neurocognitive training has 
been found to improve EF and social ability in brain injured samples 
and schizophrenic patients [56,57]. Future research could test the 
eff ectiveness of incorporating neurocognitive training into CBT for 
individuals with anxiety diagnoses following pre-treatment screening 
for EF defi cits.
ACKNOWLEDGEMENTS
Dr. Oei is now an Emeritus Professor of UQ. We would like to 
thank the participants of this study.
REFERENCES
1. Carlson SM. Developmentally sensitive measures of executive function in 
preschool children. Developmental Neuropsychology. 2005; 28: 595-616. 
https://goo.gl/rvfFXE
2. Lezak MD, Howieson D, Loring D. Neuropsychological assessment. 4th ed. 
New York: Oxford University Press. 2004. https://goo.gl/8NFT2X
3. Wilson BA, Alderman N, Burgess PW, Emslie H, Evans J. Behavioural 
assessment of the dysexecutive syndrome. Bury St Edmunds, England: 
Thames Valley Test Company. 1996. https://goo.gl/wSyDRE
4. American Psychiatric Association. Diagnostic and statistical manual of 
mental disorders: DSM-5. Washington, DC: American Psychiatric Pub. 2013. 
https://goo.gl/fKxohG
5. Airaksinen E, Larsson M, Forsell Y. Neuropsychological functions in anxiety 
disorders in population-based samples: evidence of episodic memory 
dysfunction. J Psychiatr. 2005; 39: 207-214. https://goo.gl/w6h8dx
6. Austin MP, Mitchell P, Wilhelm K, Parker G, Hickie I, Brodaty H et al. Cognitive 
function in depression: a distinct pattern of frontal impairment in melancholia? 
Psychol Med. 1999; 29: 73-85. https://goo.gl/7G66Wk
7. Nitschke JB, Mackiewicz KL. Prefrontal and anterior cingulate 
contributions to volition in depression. Int Rev Neurobiol. 2005; 67: 73-94. 
https://goo.gl/5xnMRK
8. Burgess PW, Alderman N, Evans J, Emslie H, Wilson BA. The ecological 
validity of tests of executive function. Journal of the international 
neuropsychological society. 1998; 4: 547-558. https://goo.gl/9dGoLM
9. Ludewig S, Ludewig K, Geyer MA, Hell D, Vollenweider FX. Prepulse 
inhibition deﬁ cits in patients with panic disorder. Depress Anxiety. 2002; 15: 
55-60. https://goo.gl/B5gThb
10. Snyder HR. Major depressive disorder is associated with broad impairments 
on neuropsychological measures of executive function: A meta-analysis and 
review. Psychol Bull. 2013; 139: 81-132. https://goo.gl/j34VgM
11. McDermott LM, Ebmeier KP. A meta-analysis of depression severity and 
cognitive function. J Affect Disord. 2009; 119: 1-8. https://goo.gl/ETvmA1
12. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in 
depression: a systematic review and meta-analysis. Psychol Med. 2014; 44: 
2029-2040. https://goo.gl/cbp4Uw
13. Snyder HR, Kaiser RH, Warren SL, Heller W. Obsessive-compulsive disorder 
is associated with broad impairments in executive function: A meta-analysis. 
Clinical Psychological Science. 2015; 3: 301-330. https://goo.gl/tLY1ae
14. Shin NY, Lee TY, Kim E, Kwon JS. Cognitive functioning in obsessive-
compulsive disorder: a meta-analysis. Psychol Med. 2014; 44: 1121-1130. 
https://goo.gl/aYd1Lx
15. Scott JC, Matt GE, Wrocklage KM, Crnich C, Jordan J, Southwick SM, 
Krystal JH et al. A quantitative meta-analysis of neurocognitive functioning 
in posttraumatic stress disorder. Psychol Bull. 2015; 141: 105-140. 
https://goo.gl/GnJd7u
16. Polak AR, Witteveen AB, Reitsma JB, Olff M. The role of executive function 
in posttraumatic stress disorder: A systematic review. Journal of affective 
disorders. 2012; 141: 11-21. https://goo.gl/p2WqfF
17. O’Sullivan K, Newman EF. Neuropsychological impairments in panic 
disorder: a systematic review. Journal of Affective Disorders. 2014; 167: 268-
284. https://goo.gl/ebgsfH
18. Mantella RC, Butters MA, Dew MA, Mulsant BH, Begley AE, Tracey B et al. 
Cognitive impairment in late-life generalized anxiety disorder. Am J Geriatr 
Psychiatry. 2007; 15: 673-679. https://goo.gl/RehN1k
19. Fujii Y, Kitagawa N, Shimizu Y, Mitsui N, Toyomaki A, Hashimoto N, Kako 
Y, Tanaka T, Asakura S, Koyama T, Kusumi I. Severity of generalized social 
anxiety disorder correlates with low executive functioning. Neuroscience 
letters. 2013; 543: 42-46. https://goo.gl/zUaVd2
20. Driessen E, Hollon SD, Bockting CL, Cuijpers P, Turner EH. Does 
publication bias inﬂ ate the apparent efﬁ cacy of psychological treatment for 
major depressive disorder? A systematic review and meta-analysis of US 
National Institutes of Health-funded trials. PLoS One. 2015; 10: 137864. 
https://goo.gl/VTpNrq
21. Dingle GA, Oei TP, Young RM. Mechanisms of change in negative thinking 
and urinary monoamines in depressed patients during acute treatment with 
group cognitive behavior therapy and antidepressant medication. Psychiatry 
Res. 2010; 175: 82-89. https://goo.gl/sjENQA
22. Free ML, Oei TP. Biological and psychological processes in the treatment 
and maintenance of depression. Clin Psychol Rev. 1989; 9: 653-688. 
https://goo.gl/MdBrk1
23. Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D. Efﬁ cacy of 
treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 
2015; 30: 183-192. https://goo.gl/U7mvM8
24. Tunvirachaisakul C, Gould RL, Coulson MC, Ward EV, Reynolds G, 
Gathercole RL et al. Predictors of treatment outcome in depression in later 
life: a systematic review and meta-analysis. Journal of affective disorders. 
2018; 227: 164-182. https://goo.gl/NjKxCb
25. Pimontel MA, Rindskopf D, Rutherford BR, Brown PJ, Roose SP, Sneed 
JR. A meta-analysis of executive dysfunction and antidepressant treatment 
response in late-life depression. Am J Geriatr Psychiatry. 2016; 24: 31-41. 
https://goo.gl/HVTWGP
26. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell 
JL et al. Cingulate function in depression: a potential predictor of treatment 
response. Neuroreport. 1997; 8: 1057-1061. https://goo.gl/ZNeP2a
27. Pizzagalli DA, Peccoralo LA, Davidson RJ, Cohen JD. Resting anterior 
cingulate activity and abnormal responses to errors in subjects with elevated 
depressive symptoms: A 128-channel EEG study. Human brain mapping. 
2006; 27: 185-201. https://goo.gl/8rvruz
28. Gyurak A, Patenaude B, Korgaonkar MS, Grieve SM, Williams LM, Etkin 
A. Frontoparietal activation during response inhibition predicts remission to 
antidepressants in patients with major depression. Biol Psychiatry. 2016; 79: 
274-281. https://goo.gl/eURe6G
29. Mohlman J. More power to the executive? A preliminary test of CBT plus 
executive skills training for treatment of late-life GAD. Cognitive and 
Behavioral Practice. 2008; 15: 306-316. https://goo.gl/oEjKSh
30. Mohlman J, Gorman JM. The role of executive functioning in CBT: a pilot 
study with anxious older adults. Behav Res Ther. 2005; 43: 447-465. 
https://goo.gl/envGQD
31. Johnco C, Wuthrich VM, Rapee RM. The inﬂ uence of cognitive ﬂ exibility 
on treatment outcome and cognitive restructuring skill acquisition 
during cognitive behavioural treatment for anxiety and depression in 
older adults: Results of a pilot study. Behav Res Ther. 2014; 57: 55-64. 
https://goo.gl/ra4i9A
32. Vandborg SK, Hartmann TB, Bennedsen BE, Pedersen AD, Thomsen PH. 
Can memory and executive functions in patients with obsessive–compulsive 
disorder predict outcome of cognitive behavioural therapy? Nordic journal of 
psychiatry. 2016; 70: 183-189. https://goo.gl/qNrBHY
Scientiﬁ c Journal of Depression & Anxiety
SCIRES Literature - Volume 2 Issue 1 - www.scireslit.com Page -009
33. Burgess PW, Alderman N, Wilson BA, Emslie H, Evans J. The 
dysexecutive questionnaire: Behavioural assessment of the dysexecutive 
syndrome. Bury St. Edmunds, UK: Thames Valley Test Company. 1996. 
https://goo.gl/xUcAu3
34. Oei TPS, Shaw S, Healy KL. Executive Function Deﬁ cits in Psychiatric 
Outpatients in Australia. Int J Ment Health Addict 2016; online ﬁ rst. 1-13. 
https://goo.gl/pnysZ9
35. Shaw S, Oei TP, Sawang S. Psychometric validation of the Dysexecutive 
Questionnaire (DEX). Psychological assessment. 2015; 27: 138-147. 
https://goo.gl/D36rJ7
36. Stordal E, Morken G, Mykletun A, Neckelmann D, Dahl AA. Monthly variation 
in prevalence rates of comorbid depression and anxiety in the general 
population at 63–65° North: The HUNT study. J Affect Disord. 2008; 106: 
273-278. https://goo.gl/t5q3Wq
37. Miyake A, Friedman NP, Emerson MJ, Witzki AH, Howerter A, Wager TD. 
The unity and diversity of executive functions and their contributions to 
complex “frontal lobe” tasks: A latent variable analysis. Cognitive psychology. 
2000; 41: 49-100. https://goo.gl/CXrRs9
38. American Psychiatric Association. Diagnostic and statistical manual of mental 
disorders: DSM-IV-TR. Washington, DC: American Psychiatric Pub. 2000. 
https://goo.gl/68r8Nn
39. Briggs SR, Cheek JM. The role of factor analysis in the development 
and evaluation of personality scales. J Pers. 1986; 54: 106-48. 
https://goo.gl/hyZoyC
40. Zung WW. A self-rating depression scale. Arch Gen Psychiatry. 1965; 12: 
63-70. https://goo.gl/iVU3wK
41. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical 
anxiety: psychometric properties. J Consult Clin Psychol. 1988; 56: 893. 
https://goo.gl/7ciFuA
42. Gabrys JB, Peters KA. Reliability, discriminant and predictive validity of the 
Zung Self-Rating Depression Scale. Psychol Rep. 1985; 57: 1091-1096. 
https://goo.gl/C9mSJm
43. Biggs JT, Wylie LT, Ziegler VE. Validity of the Zung self-rating depression 
scale. The Br J Psychiatry. 1978; 132: 381-385. https://goo.gl/88Ymy9
44. Dwyer L,Olsen S, Oei TPS. Cognitive-behavioral group therapy for 
heterogeneous anxiety and mood disorders in a psychiatric hospital 
outpatient clinic. Journal of Cognitive Psychotherapy. 2013; 27: 138-154. 
https://goo.gl/vQSYfB
45. Oei TPS, Boschen MJ. Clinical effectiveness of a cognitive behavioural group 
treatment program for anxiety disorders:a benchmarking study. J Anxiety 
Disord. 2009; 23: 950-957. https://goo.gl/P2Jcjp
46. Oei TP, Browne A. Components of group processes: have they contributed 
to the outcome of mood and anxiety disorder patients in a group 
cognitive-behavior therapy program? Am J Psychother. 2006; 60: 53-70. 
https://goo.gl/T8CVgy
47. Tabachnick BG, Fidell LS. Using multivariate statistics (3rd Edition). New 
York, U.S.A. Harper Collins. 1996. https://goo.gl/ExuGao
48. Aiken LS, West SG, Reno R. Multiple regression: Testing and interpreting 
interactions. Sage. 1991. https://goo.gl/HJWfYY
49. Cohen J, Cohen P. Applied Multiple Regression/Correlation Analysis for the 
Behavioral Sciences. Hillsdale, NJ: Erlbaum. 1983. https://goo.gl/oQ448q
50. Blanca MJ, Arnau J, Lopez-Montiel D, Rebecca Bendayan. Skewness 
and kurtosis in real data samples. Methodology (Gott). 2013; 9: 78-84. 
https://goo.gl/63Mm3m
51. Morris SB, De Shon RP. Combining effect size estimates in meta-analysis 
with repeated measures and independent-groups designs. Psychological 
Methods. 2002; 7: 105-125. https://goo.gl/dSBZJU
52. Zahn R, Lythe KE, Gethin JA, Green S, Deakin JF, Young AH et al. The role 
of self-blame and worthlessness in the psychopathology of major depressive 
disorder. J Affect Disord. 2015; 186: 337-341. https://goo.gl/rNUwuZ
53.  Collazzoni A, Capanna C, Bustini M, Marucci C, Prescenzo S, Ragusa M et 
al. A Comparison of Humiliation Measurement in a Depressive versus Non-
clinical Sample: A Possible Clinical Utility. J Clin Psychol. 2015; 71: 1218-
1224. https://goo.gl/DnjAao
54. Parker G, Hadzi-Pavlovic D. Is any female preponderance in depression 
secondary to a primary female preponderance in anxiety disorders? Acta 
Psychiatr Scand. 2001: 103: 252-256. https://goo.gl/BQFvFj
55. Levin HS, Brown SA, Song JX, McCauley SR, Boake C, Contant CF et al. 
Depression and posttraumatic stress disorder at three months after mild to 
moderate traumatic brain injury. J Clin Exp Neuropsychol 2001; 23: 754-769. 
https://goo.gl/1EqTi7
56. Robertson IH. Cognitive neuroscience and brain rehabilitation: A 
promise kept. J Neurol Neurosurg Psychiatry. 2002; 73: 357-359. 
https://goo.gl/b5njXW
57. Robertson IH, Murre JM. Rehabilitation of brain damage: brain plasticity 
and principles of guided recovery. Psychol Bull. 1999; 125: 544-575. 
https://goo.gl/aHEFJJ.
